High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer

Miguel, D. de ; Gallego-Lleyda, A. ; Ayuso, J. M. (Universidad de Zaragoza) ; Pejenaute-Ochoa, D. ; Jarauta, V. ; Marzo, I. (Universidad de Zaragoza) ; Fernández, L. J. (Universidad de Zaragoza) ; Ochoa, I. ; Conde, B. (Universidad de Zaragoza) ; Anel, A. (Universidad de Zaragoza) ; Martinez-Lostao, L. (Universidad de Zaragoza)

Resumen: During the last years, a great effort has been invested into developing new TRAIL formulations with increased bioactivity, trying to overcome the resistance to conventional soluble TRAIL (sTRAIL) exhibited by many primary tumours. In our group, we have generated artificial lipid nanoparticles decorated with sTRAIL (LUV-TRAIL), emulating the physiological TRAIL-containing exosomes by which T-cells release TRAIL upon activation. We already demonstrated that LUV-TRAIL has greater cytotoxicity against both chemoresistant haematologic tumour cells and epithelial carcinoma cells compared to a form of sTRAIL similar to that used in clinical trials. In this study we have tested LUV-TRAIL in several human colon cancer cell lines with different sensitivity to sTRAIL. LUV-TRAIL significantly improved sTRAIL cytotoxicity in all colon cancer cell lines tested. Trying to ascertain the molecular mechanism by which LUV-TRAIL exhibited improved cytotoxicity, we demonstrated that TRAIL-coated lipid nanoparticles were able to activate DR5 more efficiently than sTRAIL, and this relied on LUV-TRAIL ability to promote DR5 clustering on the cell surface. Moreover, we show that TRAIL molecules are arranged in higher order oligomers only in LUV-TRAIL, which may explain their enhanced DR5 clustering ability. Finally, LUV-TRAIL showed significantly better antitumour activity than sTRAIL in an in vivo model using HCT-116 xenograft tumours in nude mice, validating its potential clinical application.

Idioma: Inglés

DOI: 10.1016/j.canlet.2016.10.005

Año: 2016

Publicado en: CANCER LETTERS 383, 2 (2016), 250-260
ISSN: 0304-3835

Factor impacto JCR: 6.375 (2016)

Categ. JCR: ONCOLOGY rank: 25 / 217 = 0.115 (2016) - Q1 - T1

Factor impacto SCIMAGO: 2.371 - Oncology (Q1) - Cancer Research (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI13-00416
Financiación: info:eu-repo/grantAgreement/ES/MICINN/SAF2013-48626-C2-1-R
Financiación: info:eu-repo/grantAgreement/ES/MINECO/DPI2011-28262-C04-01

Tipo y forma: Artículo (PostPrint)

Área (Departamento): Area Histología (Dpto. Anatom.Histolog.Humanas)
Área (Departamento): Área Inmunología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Mec.Med.Cont. y Teor.Est. (Dpto. Ingeniería Mecánica)